Coromandel International Limited has announced the commencement of trial production at its new Phosphoric Acid and Sulphuric Acid plants located at Kakinada, Andhra Pradesh. The company informed stock exchanges about this significant operational milestone through a regulatory filing under SEBI Regulation 30.

Plant Specifications and Capacity

The newly commissioned facilities represent a substantial addition to the company's manufacturing capabilities. The plants have been designed with specific production capacities to meet the company's strategic requirements.

Operational Timeline and Ramp-up Strategy

The commissioning aligns with the company's earlier timeline indication for Quarter 4 of FY 2025-26. Operations are currently being stabilised, with the company planning a phased approach to achieve full rated capacity. This measured ramp-up strategy ensures optimal operational efficiency and quality standards.

The project was initially announced through an earlier intimation dated January 30, 2024, demonstrating the company's commitment to its planned expansion timeline.

Strategic Impact on Operations

The commissioning of these plants marks a transformational development for Coromandel International's Kakinada unit. The facility now operates as a fully integrated manufacturing complex, significantly enhancing the company's overall production capacity.

Key strategic benefits include:

• Enhanced Production Capacity: Substantial increase in manufacturing capabilities
• Import Dependency Reduction: Decreased reliance on imported raw materials
• Raw Material Security: Strengthened supply chain for fertiliser manufacturing
• Operational Integration: Complete integration of the Kakinada facility

The development positions the company to better serve market demand while improving operational efficiency through vertical integration. The reduced dependency on imports provides greater control over raw material costs and supply chain reliability, which is particularly important for fertiliser manufacturing operations.

Coromandel International has completed the allotment of equity shares under its Employee Stock Option Plan, marking another step in its employee incentive program. The Stakeholders Relationship Committee approved the allotment on February 24, 2026, demonstrating the company's commitment to employee participation in ownership.

ESOP Allotment Details

The committee approved the allotment of 19,230 equity shares under the ESOP Scheme 2016. These shares carry a face value of Re. 1 each and are fully paid up to the option grantees. The newly allotted shares will rank pari-passu with existing equity shares, ensuring equal rights and privileges across all shareholdings.

Impact on Share Capital

The allotment has resulted in an increase in the company's authorized and issued share capital. The share capital structure reflects the addition of the newly allotted ESOP shares to the existing equity base.

Regulatory Compliance

Coromandel International has informed both the National Stock Exchange of India Limited and BSE Limited about this allotment in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company secretary and compliance officer B. Shanmugasundaram signed the regulatory filing, ensuring proper documentation and transparency in the allotment process.

The ESOP allotment represents the company's ongoing efforts to align employee interests with shareholder value creation through equity participation programs.